Abstract

The prevalence of various kidney diseases has become a significant threat to global public health and one of the leading causes of severe morbidity and high mortality. Multiple extrinsic or intrinsic factors, including drug or chemotoxicity, aging biomarkers, and various aging-related disorders, may exacerbate multiple kidney diseases and subsequently lead to end-stage renal disease (ESRD). In addition, the complications of kidney pathologies further pose challenges to current clinical practices. However, amid the development of various novel therapeutic approaches against kidney diseases, the interest in natural products or nutraceutical-based treatments has been growing and active in research on renal disorders. Amongst these, luteolin-a flavone, has been shown to be potent in combatting kidney disorders by effectively preventing and ameliorating the progression of various kidney biomarkers and associated pathologies. Therefore, this systemic review assimilates the evidence of numerous in-vitro and in-vivo studies along with the progress in luteolin-based drug development to enlighten its pharmacological potency in treating kidney disorders. The existing reports strongly support the promising therapeutic benefits of luteolin and thus, the review suggests conducting clinical studies to establish it as a potent therapeutic agent against kidney diseases.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call